Alimentary pharmacology & therapeutics
Cure8 research brief
Why This Matters
The study addresses a practical question for people with IBD: whether sequencing anti-TNF therapy after a biologic from a different class affects how well the anti-TNF works. Shorter durability — especially in ulcerative colitis — could influence choices about treatment order.
Who Should Pay Attention
Clinicians who prescribe biologics, researchers studying treatment sequencing, and patients currently on or considering biologic therapy (especially those thinking about switching classes).
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This multicentre study used the ENEIDA registry and compared patients who received second-line anti-TNF after a non–anti-TNF biologic to matched controls receiving first-line anti-TNF or anti-TNF after another anti-TNF.
In Crohn's disease the study found higher risk of treatment discontinuation for anti-TNF given after a different MOA (most commonly ustekinumab) but no clear differences in short- or long-term clinical effectiveness.
In ulcerative colitis the study found lower durability and lower remission rates both short- and long-term when anti-TNF was given after a different MOA (most commonly vedolizumab). How to use this: These results are from registry observational data and describe associations, not randomized comparisons.
They may inform discussions between patients and clinicians about sequencing biologic therapies, but individual decisions should consider prior response, safety, patient preferences, and other clinical factors.
Keep In Mind
This is an observational registry analysis (ENEIDA) using propensity-score matching; it reports associations rather than randomized trial outcomes. The abstract provides the study summary but not full methodological or subgroup details.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationAlimentary pharmacology & therapeutics
AuthorsCarmen Yagüe Caballero, Santiago García López, Ana Royo Esteban +83 more
InstitutionServicio de Aparato Digestivo, Hospital Universitario Miguel Servet, Zaragoza, Spain.
Study typeJournal article
Indexed viaPubMed
Source typeResearch paper
PublishedAug 12, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lilly nets a second FDA okay for Omvoh, in Crohn's disease
A new FDA approval means another IL-23 option is formally available for people with moderately to severely active Crohn’s disease, including patients whose disease did not respond to other therapies. This could affect...
When are biologic drugs an option for Crohn’s disease?
Biologics are a common and important treatment option for people with moderate to severe Crohn’s disease; knowing when they’re used and their potential risks helps patients discuss treatment choices with their care team.
VIDEO: Longstanding therapies, recent approvals provide options in Crohn’s disease
This video quickly outlines the range of medical treatments now available for Crohn’s disease, including newer approvals. Knowing drug classes and recent options can help patients and clinicians discuss treatment plans...